Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07460336

Effects of Cofrogliptin on Beta-Cell Function in LADA Patients

This single-center, randomized, open-label, controlled study aims to evaluate the effect of cofrogliptin on pancreatic β-cell function in adults with latent autoimmune diabetes in adults (LADA). Following a screening period of up to 6 weeks, 84 eligible participants will be randomized in a 1:1 ratio via a sealed-envelope method, stratified by baseline GADA titer (≥0.3 vs <0.3). Participants will be assigned to one of two treatment arms: (1) metformin (with or without insulin) plus vitamin D3, or (2) metformin (with or without insulin) plus vitamin D3 and cofrogliptin. Cofrogliptin will be administered orally at a dose of 10 mg once every 2 weeks, and vitamin D3 at 2000 IU once daily, for a total treatment duration of 52 weeks. Study visits are planned at baseline and at Weeks 12, 26, 38, and 52, during which mixed-meal tolerance tests (MMTT) and other protocol-specified assessments will be conducted.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Latent Autoimmune Diabetes in Adults (LADA) Autoimmune Diseases Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Immune System Diseases Latent Autoimmune Diabetes in Adults Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

Latent autoimmune diabetes in adults (LADA) is a form of autoimmune diabetes characterized by the progressive destruction of pancreatic beta cells. Preclinical and clinical evidence suggests that dipeptidyl peptidase-4 (DPP-4) inhibitors and vitamin D possess immunomodulatory effects that may help preserve residual beta-cell function. Cofrogliptin is a novel, ultra-long-acting DPP-4 inhibitor.

This study will enroll patients with LADA who will first enter a screening period. Eligible participants will be randomized (1:1) into two parallel arms on Day 1. The experimental group will receive cofrogliptin and vitamin D3 in addition to their background therapy. The active comparator group will receive vitamin D3 plus background therapy. Background therapy includes metformin, with insulin permitted and adjusted per investigator's judgment. Follow-up clinic visits are scheduled at Weeks 12, 26, 38, and 52. Efficacy will be assessed through MMTT-derived C-peptide and glucose measurements, as well as other glycemic indices. Safety will be monitored through the recording of adverse events, laboratory tests, and vital signs throughout the 52-week treatment period.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. Voluntarily signed informed consent.
  • 2. Age 18 to 70 years, inclusive.
  • 3. Diagnosed with LADA, defined as meeting all of the following:
  • (1) Meets 1999 WHO criteria for diabetes mellitus.
  • (2) Age at diagnosis of diabetes ≥ 18 years.
  • (3) Positive for at least one islet autoantibody (GADA, IA-2A, or ZnT8A).
  • (4) Did not require continuous insulin therapy for at least 6 months after diagnosis.
  • 4. Stimulated C-peptide ≥ 200 pmol/L.
  • 5. Glycated Hemoglobin (HbA1c) ≤ 9.0%.
  • 6. For women of childbearing potential, must agree to use a highly effective method of contraception throughout the study.

Exclusion criteria

  • 1. Pregnant, breastfeeding, or planning to become pregnant during the study.
  • 2. Gestational diabetes or other specific types of diabetes.
  • 3. Known hypersensitivity to Cogliptin, Vitamin D3, or their excipients.
  • 4. Use of DPP-4 inhibitors, GLP-1 receptor agonists, or thiazolidinediones (TZDs) within 8 weeks prior to randomization.
  • 5. Hypercalcemia (serum calcium above the upper limit of the normal range).
  • 6. Systemic corticosteroid therapy (oral or IV) for more than 7 consecutive days within 6 months prior to screening.
  • 7. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times the upper limit of normal (ULN), or total bilirubin > 2 times ULN.
  • 8. Estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m².
  • 9. History of acute diabetic complications such as diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state.
  • 10. History of pancreatitis or pancreatic surgery.
  • 11. New York Heart Association (NYHA) class III or IV congestive heart failure, or known left ventricular ejection fraction (LVEF) < 40%.
  • 12. History of malignancy.
  • 13. Severe psychiatric illness.
  • 14. History of alcohol or illicit drug dependence.
  • 15. Any other severe systemic disease that the investigator deems unsuitable for enrollment.

Treatment and study plan

Cofrogliptin

Drug

5 mg/tablet, oral; 2 tablets (10 mg) once every 2 weeks. Administered from randomization through Week 52.

Vitamin D3

Drug

400 IU/capsule, oral; 5 capsules (2000 IU) once daily. Administered from randomization through Week 52.

metformin

Drug

Background therapy. Oral; typical daily dose 1.5 g, adjustable from 1.0 to 1.7 g/day per investigator judgment.

Insulin

Drug

Background therapy, as needed. Subcutaneous; individualized daily dose per investigator judgment.

Primary outcomes

  1. Change From Baseline in 2-hour Mixed-Meal Tolerance Test (MMTT) C-peptide Area Under the Curve (AUC)

    Time frame: Baseline, Week 52

    Change from baseline in the area under the curve from 0 to 120 minutes (AUC0-120) for serum C-peptide during a mixed-meal tolerance test (MMTT), calculated using the trapezoidal rule from C-peptide measured at 0, 60, and 120 minutes.

Secondary outcomes

  1. Change From Baseline in 2-hour MMTT C-peptide AUC at Weeks 12, 26, and 38

    Time frame: Baseline, Week 12, Week 26, Week 38

    The 2-hour Mixed-Meal Tolerance Test (MMTT) C-peptide Area Under the Curve (AUC) will be calculated using the trapezoidal rule from C-peptide levels measured at 0, 60, and 120 minutes during the MMTT. Change from baseline is defined as the post-baseline value minus the baseline value. This outcome assesses the overall C-peptide response to a standardized meal stimulus.

  2. Change From Baseline in Fasting C-peptide (FCP)

    Time frame: Baseline, Week 12, Week 26, Week 38, Week 52

    Fasting C-peptide (FCP) is measured from a blood sample taken after an overnight fast of at least 8 hours. It reflects the basal insulin secretion capacity of pancreatic β-cells.

  3. Change From Baseline in 60-Minute Post-Meal C-peptide

    Time frame: Baseline, Week 12, Week 26, Week 38, Week 52

    Serum C-peptide will be measured at 60 minutes during the mixed-meal tolerance test (MMTT). Change from baseline is defined as the post-baseline 60-minute C-peptide value minus the baseline 60-minute C-peptide value. This measurement assesses the early dynamic response of pancreatic β-cells to a meal stimulus.

  4. Change From Baseline in 120-Minute Post-Meal C-peptide

    Time frame: Baseline, Week 12, Week 26, Week 38, Week 52

    Serum C-peptide will be measured at 120 minutes during the mixed-meal tolerance test (MMTT). Change from baseline is defined as the post-baseline 120-minute C-peptide value minus the baseline 120-minute C-peptide value. This measurement assesses the late dynamic response of pancreatic β-cells to a meal stimulus.

  5. Change From Baseline in Glycated Hemoglobin (HbA1c)

    Time frame: Baseline, Week 26, Week 52

    HbA1c provides an indication of the average blood glucose levels over the preceding 2-3 months. This outcome measures the long-term glycemic control in participants.

  6. Proportion of Participants Achieving HbA1c < 7.0%

    Time frame: Week 12, Week 26, Week 38, Week 52

    The percentage of participants in each group who achieve a target HbA1c level of less than 7.0% (53 mmol/mol), which is a standard therapeutic goal for glycemic control in adults with diabetes.

  7. Change From Baseline in Mean Daily Insulin Dose

    Time frame: Baseline, Week 12, Week 26, Week 38, Week 52

    The change from baseline in the mean daily insulindose will be calculated as units per kilogram per day (u/kg/day), based on data recorded in participant diaries. This outcome is designed to evaluate the effect of the intervention on the requirement for exogenous insulin.

  8. Change From Baseline in Homeostatic Model Assessment of β-cell function (HOMA-β)

    Time frame: Baseline, Week 12, Week 26, Week 38, Week 52

    HOMA-β is calculated using fasting glucose and fasting C-peptide levels. It provides an estimate of basal pancreatic β-cell function. Change from baseline is defined as the post-baseline value minus the baseline value.

  9. Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)

    Time frame: Baseline, Week 12, Week 26, Week 38, Week 52

    HOMA-IR is calculated using fasting glucose and fasting C-peptide levels. It provides an estimate of insulin resistance. Change from baseline is defined as the post-baseline value minus the baseline value.

  10. Change From Baseline in Glutamic Acid Decarboxylase Autoantibody (GADA) Titers

    Time frame: Baseline, Week 52

    GADA is a marker of the autoimmune process in LADA. Change from baseline is defined as the Week 52 value minus the baseline value. Changes in its titers may reflect modulation of the autoimmune response.

  11. Change From Baseline in Insulinoma-Associated Antigen-2 Autoantibody (IA-2A) Titers

    Time frame: Baseline, Week 52

    IA-2A is a marker of the autoimmune process in LADA. Changes in its titers may reflect modulation of the autoimmune response. Change from baseline is defined as the Week 52 value minus the baseline value.

  12. Change From Baseline in Zinc Transporter 8 Autoantibody (ZnT8A) Titers

    Time frame: Baseline, Week 52

    ZnT8A is a marker of the autoimmune process in LADA. Changes in its titers may reflect modulation of the autoimmune response. Change from baseline is defined as the Week 52 value minus the baseline value.

  13. Change From Baseline in Body Weight

    Time frame: Baseline, Week 12, Week 26, Week 38, Week 52

    Body weight will be measured in kilograms (kg) at scheduled visits. Change from baseline is defined as the post-baseline value minus the baseline value.

  14. Change From Baseline in Body Mass Index (BMI)

    Time frame: Baseline, Week 12, Week 26, Week 38, Week 52

    Body Mass Index (BMI) will be calculated as weight in kilograms divided by the square of height in meters (kg/m²) to assess changes in body composition. Change from baseline is defined as the post-baseline value minus the baseline value.

Other outcomes

  1. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Throughout the study (52 weeks)

    Safety will be evaluated by recording the number of participants who experience treatment-emergent adverse events and serious adverse events throughout the study, including events of special interest such as severe hypoglycemia and potential hypercalcemia.

  2. Number of participants with Clinically Significant Abnormal Vital Signs, Laboratory Tests, or ECG Findings

    Time frame: At scheduled visits through Week 52

    Safety will be monitored by assessing the number (and proportion) of participants who experience clinically significant changes from baseline in vital signs (systolic and diastolic blood pressure, heart rate, body temperature), clinical laboratory parameters (hematology, clinical chemistry, and urinalysis), or 12-lead electrocardiogram (ECG) findings. Clinically significant changes will be evaluated by the investigator. Each participant will be counted once if any qualifying abnormality occurs.

Study contacts

Contact information is provided by the study sponsor or research team.

Chuqing Cao, PhD

CONTACT

[email protected]

Zhiguang Zhou, MD,PhD

CONTACT

[email protected]

+8673185292154

Sponsors and collaborators

Lead sponsor

Second Xiangya Hospital of Central South University

Other

Registry information

Official study title

Key Effects of Cofrogliptin on Beta-cell Function in Adults With Latent Autoimmune Diabetes (LADA): A Single-Center, Randomized, Controlled Trial - KOLA Study

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Mar 10, 2026
Registry last updated
May 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.